{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-239015","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.576595+00:00","generated_at":"2026-05-17T03:53:09.636298+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Karyopharm closes $131M debt financing; issues 9% convertible notes, waives defaults","bullets":["Borrowed $12.5M under amended credit agreement; issued $15M 2028 and $103.5M 2029 convertible notes at 9%.","Specified defaults under existing credit agreement waived via Oct 7, 2025 First Amendment.","As of Oct 14, 2025, common shares outstanding: 15,926,939.","Financing includes warrants and pre-funded warrants; previously announced on Oct 8, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-239015","json":"https://secwatch.observer/filing/0001193125-25-239015.json","markdown":"https://secwatch.observer/filing/0001193125-25-239015.md","text":"https://secwatch.observer/filing/0001193125-25-239015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312525239015/0001193125-25-239015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312525239015/d81116d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:53:09.636298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a7715569dca69da7cccf82ecc5439e9cac276951","claim":"Karyopharm Therapeutics Inc. incurred credit facility of $12.5 million with term loan lenders at not specified maturing not specified.","evidence_excerpt":"On the Closing Date and as disclosed in the Current Report on Form 8-K filed by the Company on October 8, 2025, the Company borrowed $12.5 million under its credit and guaranty agreement, as amended, by the First Amendment and Waiver to Credit and Guaranty Agreement dated as of October 7, 2025.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312525239015/0001193125-25-239015-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$12.5 million"},{"label":"Counterparty","value":"term loan lenders"},{"label":"Rate","value":"not specified"},{"label":"Maturity","value":"not specified"},{"label":"Event","value":"incurrence"}]},{"claim_id":"f3d663b070a50c4fdd9060fbe17cf5d1456c6c3d","claim":"Karyopharm Therapeutics Inc. incurred convertible notes of $15.0 million aggregate principal amount of 9.00% senior secured convertible notes due 2028 and $103.5 million aggregate with holders of convertible notes and other investors at 9.00% maturing 2028 and 2029.","evidence_excerpt":"On the Closing Date and as disclosed in the Current Report on Form 8-K filed by the Company on October 8, 2025, the Company issued $15.0 million aggregate principal amount of 9.00% senior secured convertible notes due 2028 and $103.5 million aggregate principal amount of 9.00% senior secured convertible notes due 2029.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312525239015/0001193125-25-239015-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$15.0 million aggregate principal amount of 9.00% senior secured convertible notes due 2028 and $103.5 million aggregate"},{"label":"Counterparty","value":"holders of convertible notes and other investors"},{"label":"Rate","value":"9.00%"},{"label":"Maturity","value":"2028 and 2029"},{"label":"Event","value":"incurrence"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}